Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joëlle M Hoebert

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Health Policy (Amsterdam, Netherlands)|November 15, 2011
Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countriesJoëlle M Hoebert, Aukje K Mantel-Teeuwisse, Liset van Dijk, et al.
Journal of Pharmaceutical Policy and Practice|April 26, 2014
National medicines policies - a review of the evolution and development processesJoëlle M Hoebert, Liset van Dijk, Aukje K Mantel-Teeuwisse, et al.
Annals of Family Medicine|January 11, 2012
Reimbursement restriction and moderate decrease in benzodiazepine use in general practiceJoëlle M Hoebert, Patrick C Souverein, Aukje K Mantel-Teeuwisse, et al.
Pharmacoepidemiology and Drug Safety|February 26, 2011
Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case studyJoëlle M Hoebert, Aukje K Mantel-Teeuwisse, Liset van Dijk, et al.
BMJ Surgery, Interventions, & Health Technologies|November 3, 2025
Development of a minimum checklist to assess the quality of evidence produced using registry data for the evaluation of medical device safety and performanceLotje A Hoogervorst, Rob G H H Nelissen, Tom Melvin, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Health Policy (Amsterdam, Netherlands)|November 15, 2011
Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countriesJoëlle M Hoebert, Aukje K Mantel-Teeuwisse, Liset van Dijk, et al.
Journal of Pharmaceutical Policy and Practice|April 26, 2014
National medicines policies - a review of the evolution and development processesJoëlle M Hoebert, Liset van Dijk, Aukje K Mantel-Teeuwisse, et al.
Annals of Family Medicine|January 11, 2012
Reimbursement restriction and moderate decrease in benzodiazepine use in general practiceJoëlle M Hoebert, Patrick C Souverein, Aukje K Mantel-Teeuwisse, et al.
Pharmacoepidemiology and Drug Safety|February 26, 2011
Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case studyJoëlle M Hoebert, Aukje K Mantel-Teeuwisse, Liset van Dijk, et al.
BMJ Surgery, Interventions, & Health Technologies|November 3, 2025
Development of a minimum checklist to assess the quality of evidence produced using registry data for the evaluation of medical device safety and performanceLotje A Hoogervorst, Rob G H H Nelissen, Tom Melvin, et al.
Pageof 1